biostudies-literatureMcMullan BWorld Health Organizationmyae038https://www.ebi.ac.uk/biostudies/studies/S-EPMC11210620biostudies-literatureUnknown62(6)This systematic review evaluates the current global impact of invasive infections caused by Pneumocystis jirovecii (principally pneumonia: PJP), and was carried out to inform the World Health Organization Fungal Priority Pathogens List. PubMed and Web of Science were used to find studies reporting mortality, inpatient care, complications/sequelae, antifungal susceptibility/resistance, preventability, annual incidence, global distribution, and emergence in the past 10 years, published from January 2011 to February 2021. Reported mortality is highly variable, depending on the patient population: In studies of persons with HIV, mortality was reported at 5%-30%, while in studies of persons without HIV, mortality ranged from 4% to 76%. Risk factors for disease principally include immunosuppressMedical mycologyFeatures and global impact of invasive fungal infections caused by Pneumocystis jirovecii: A systematic review to inform the World Health Organization fungal priority pathogens list.PMC11210620001McMullan BMorrissey CONahrgang SASati HTacconelli EAlastruey-Izquierdo ATanti DOladele RGalas MShin JHGovender NPFord NPHeim JBeardsley JKim HYDao AHuttner BGigante VAlffenaar JWfalseFeatures and global impact of invasive fungal infections caused by Pneumocystis jirovecii: A systematic review to inform the World Health Organization fungal priority pathogens list.This systematic review evaluates the current global impact of invasive infections caused by Pneumocystis jirovecii (principally pneumonia: PJP), and was carried out to inform the World Health Organization Fungal Priority Pathogens List. PubMed and Web of Science were used to find studies reporting mortality, inpatient care, complications/sequelae, antifungal susceptibility/resistance, preventability, annual incidence, global distribution, and emergence in the past 10 years, published from January 2011 to February 2021. Reported mortality is highly variable, depending on the patient population: In studies of persons with HIV, mortality was reported at 5%-30%, while in studies of persons without HIV, mortality ranged from 4% to 76%. Risk factors for disease principally include immunosuppress2024-01-01T00:00:00Z2024 Jun2026-05-05T18:15:50.037Z2025-04-19T18:33:25.899ZS-EPMC112106203893591010.1093/mmy/myae038